UK markets closed

Editas Medicine, Inc. (0IFK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
34.23-1.52 (-4.25%)
At close: 3:02PM BST
Sign in to post a message.
  • A
    Anonymous
    This stock was in 20s and low 30s when EDIT-101 was stalling and no other trials imminent. EDIT-101 is fully progressing and EDIT-301 will be dosing soon, not to mention their oncology work with BMY and iNK cells around the corner. Time to rejoin peers near their valuations.
  • R
    RV
    Lisa Michaels -- Chief Medical Officer after earnings:

    The data showed that NK cells that have been edited to knockout CISH and TGF beta with our proprietary CRISPR/Cas12a enzyme demonstrates superior tumor killing ability when compared to unedited NK cells. We've also showed that NK cells demonstrated improved cytotoxicity and enhanced metabolic function in certain tumor micro environments. These findings support our belief that edited NK cells will play an important role in the future treatment of solid tumor cancers. And we're concurrently exploring additional edits containing [indecipherable] to further enhance the activity of NK cells. And so I will look forward to updating you more on that program before the end of the year.

    ---------------------

    NKTX has a program to use edited cells but they are going to knockout just TGF beta and not CISH. I am not sure if FATE and GMDA if they are using NK cells with or without editing.

    EDIT is looking at additional edits to make NK cells more effective.
  • R
    Rune
    Today, the Company announced Mark S. Shearman, Ph.D., will be joining Editas as Chief Scientific Officer, in June 2021. Dr. Shearman has more than 30 years of experience in drug discovery and development across multiple therapeutic modalities, and his expertise in neurology, ophthalmology, and immunology will strengthen the Company’s existing pipeline. Dr. Shearman will join Editas Medicine from Applied Genetic Technologies Corporation (AGTC), where he is currently serving as Chief Scientific Officer and is responsible for leading the company's product candidate selection process, pre-clinical and translational research, and long-term research and development planning. Prior to AGTC, Dr. Shearman served as Senior Vice President of Research & Early Development at EMD Serono, Inc., the U.S. and Canadian subsidiary of Merck KGaA. Previously, Dr. Shearman was Executive Director of Merck & Co. Research Laboratories in Boston, and Senior Director at the Merck Sharp & Dohme Research Laboratories Neuroscience Research Centre in the United Kingdom. Dr. Shearman earned a B.Sc. from the University of Bristol, U.K., and a Ph.D. from the University of Nottingham, U.K. He also conducted academic research at institutes in Japan and Germany.
  • A
    Anonymous
    When the Nasdaq starts climbing again, this will quickly be back to 40, need to break that.
  • A
    Anonymous
    From CC: they have dosed 4 patients in EDIT-101 trial and have the 5th and 6th scheduled. They hope to get approval this summer to dose mid-dose pediatric patients, which will have the best chance of most visual benefit.

    They have patients lined up for EDIT-301, but the process to get from signing them up to actual dosing is about a 4 to 5 month process.
  • M
    Mick
    Editas announced Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development for the Company’s pipeline of experimental medicines.
  • A
    Anonymous
    Based on CEO’s words about partnerships and their importance for EDIT, I will be disappointed if we don’t hear about a major partnership within the next couple of quarters.
  • W
    Widespread Panic
    Interesting CSO pickup. Honestly, pleasantly surprised with the speed of the move.

    Shearman showed good progression through 11+ years at Merck/Merck subsidiary. Which is always a promising sign. AGTC seems like a bit of a flop but a relevant research path in candidates within the eye. Below is their lead research effort.

    AGTC's lead product candidates focus on X-linked retinitis pigmentosa and, achromatopsia, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also using its gene therapy expertise to expand into disease indications with large market opportunity such as dry AMD and optogenetics, as well as the CNS, and inherited deafness with its partner Otonomy.
  • A
    Anonymous
    Sentiment is bad here, but there are many eyes watching closely. Time for a turning of the tide tomorrow.
  • n
    northnode3g
    Still less than 1m volume. Wait to see after tomorrow’s presentation what volume looks like. I’m really hoping for CEO to come out with good visibility on EDIT-101 & 301.
  • A
    Anonymous
    The following is a distinct possibility for EDIT-101: adult low-dose and mid-dose patients are not exhibiting distinct visual benefits to date, but are showing indications of successful editing, which is why they are eager to get to pediatric mid-dose who will have a much better chance of exhibiting visual benefit. The photoreceptors can be restored, but the brain must still be able to recognize and process the information to achieve visual improvement. That’s my layman’s interpretation, let me know if you understand differently.
  • R
    RV
    Just out:

    Brad Loncar@bradloncar$CRSP and $NKTX to collaborate on CAR NK cell product candidates.4:02 PM · May 6, 2021·TweetDeck

    So EDIT will have to pick FATE or GMDA in NK but should look for TRIL- to use Neutrophils - for ? Edited CAR-Neutophils- CRSP may grab them.
  • A
    Anonymous
    Let’s hope this is just the beginning of strong, positive updates and guidance this week and going forward.
  • N
    Nikita
    they have increased R&D costs and are attracting experienced staff, which is good
  • n
    northnode3g
    Hope CEO & others can change the narrative May 5 earnings. EDIT has a lot of potential and can certainly go higher if management executes better than before.
  • A
    Anonymous
    People who are negative about EDIt are judging what has happened, not what is happening.
  • i
    iamaverb
    When looking at the market over the past 100 days, I am reminded of JOB 3:25 "“the thing I feared the most has come upon me, and that which I was afraid of has come unto me.” Though T had a personality few could tolerate, he at least got it done. Function over form.
    Personally I see no end in sight.
  • A
    Anonymous
    The sentiment could change quickly if we hear the right news over the next few months, hopefully starting 5/5/21.
  • T
    Tom
    EDIT just announced "Gene edited USH2A exon 13 deletion restored USH2 protein complex expression and rescued deficits in photoreceptor morphology in human retinal organoids".
  • n
    northnode3g
    NTLA earnings expected tomorrow, BEAM next week